ClonOrgan raises 200M yuan to advance xenotransplant trials
What's the deal? ClonOrgan, a Chengdu-based company working in xenotransplantation, has closed a Series A extension round of more than 200 million yuan (about $29.6 million). CAS StarDealroom has a profile for this one. Try Dealroom → led the round, with Lenovo Venture CapitalDealroom has a profile for this one. Try Dealroom →, Muyuan GroupDealroom has a profile for this one. Try Dealroom →, Weigao Blood PurificationDealroom has a profile for this one. Try Dealroom →, Huali GroupDealroom has a profile for this one. Try Dealroom →, Huafang CapitalDealroom has a profile for this one. Try Dealroom →, and Chengdu Kechuang Investment joining.
Who else backed it? Existing investors Betta FundDealroom has a profile for this one. Try Dealroom → and Guanghe VCDealroom has a profile for this one. Try Dealroom → added to their stakes. The round was announced in August 2026.
What's the endgame? ClonOrgan develops technology to transplant animal organs into humans — a field aimed at easing chronic donor-organ shortages. The company will use the funds to file and advance clinical trials, expand production of DPF-grade medical donor pigs, build out an industrial base, and develop a new generation of multi-gene-edited donor pigs.
Why now? This is ClonOrgan's third tranche within its Series A, signalling a quick re-raise as it moves from research towards clinical application. The funds will support clinical-trial filings, DPF-grade donor-pig production and further development of multi-gene-edited donor pigs.
Image credit: Generated with Gemini
Read more: Jiemian
